This article is free to access.
Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer.Methods: The percentage of dendritic cells and CD4+ and CD8+ T cells in the spleen (flow cytometry), cytokines' release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 μg/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test.Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-γ and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-β levels were decreased. There was also an increase in macrophage's activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively).Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment. © 2012 de Matos et al.; licensee BioMed Central Ltd.
de Matos, D. C., de Ribeiro, L. C. A., Tansini, A., Ferreira, L. S., Placeres, M. C. P., Colombo, L. L., & Carlos, I. Z. (2012). Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment. BMC Complementary and Alternative Medicine, 12. https://doi.org/10.1186/1472-6882-12-107